215 related articles for article (PubMed ID: 18710896)
21. A homologue of the Drosophila headcase protein is a novel tumor marker for early-stage colorectal cancer.
Chien CC; Chang CC; Yang SH; Chen SH; Huang CJ
Oncol Rep; 2006 Apr; 15(4):919-26. PubMed ID: 16525680
[TBL] [Abstract][Full Text] [Related]
22. Similar chromosomal changes in cisplatin and oxaliplatin-resistant sublines of the H69 SCLC cell line are not associated with platinum resistance.
Stordal B; Peters G; Davey R
Genes Chromosomes Cancer; 2006 Dec; 45(12):1094-105. PubMed ID: 16967470
[TBL] [Abstract][Full Text] [Related]
23. Urinary excretion of carnitine as a marker of proximal tubular damage associated with platin-based antineoplastic drugs.
Haschke M; Vitins T; Lüde S; Todesco L; Novakova K; Herrmann R; Krähenbühl S
Nephrol Dial Transplant; 2010 Feb; 25(2):426-33. PubMed ID: 19736245
[TBL] [Abstract][Full Text] [Related]
24. Organic cation transporter OCT/SLC22A and H(+)/organic cation antiporter MATE/SLC47A are key molecules for nephrotoxicity of platinum agents.
Yonezawa A; Inui K
Biochem Pharmacol; 2011 Mar; 81(5):563-8. PubMed ID: 21144842
[TBL] [Abstract][Full Text] [Related]
25. Drug specificity and intestinal membrane localization of human organic cation transporters (OCT).
Müller J; Lips KS; Metzner L; Neubert RH; Koepsell H; Brandsch M
Biochem Pharmacol; 2005 Dec; 70(12):1851-60. PubMed ID: 16263091
[TBL] [Abstract][Full Text] [Related]
26. Inhibition of G1/S transition potentiates oxaliplatin-induced cell death in colon cancer cell lines.
Rakitina TV; Vasilevskaya IA; O'Dwyer PJ
Biochem Pharmacol; 2007 Jun; 73(11):1715-26. PubMed ID: 17343830
[TBL] [Abstract][Full Text] [Related]
27. A colorectal cancer expression profile that includes transforming growth factor beta inhibitor BAMBI predicts metastatic potential.
Fritzmann J; Morkel M; Besser D; Budczies J; Kosel F; Brembeck FH; Stein U; Fichtner I; Schlag PM; Birchmeier W
Gastroenterology; 2009 Jul; 137(1):165-75. PubMed ID: 19328798
[TBL] [Abstract][Full Text] [Related]
28. Different accumulation of cisplatin, oxaliplatin and JM216 in sensitive and cisplatin-resistant human cervical tumour cells.
Martelli L; Di Mario F; Ragazzi E; Apostoli P; Leone R; Perego P; Fumagalli G
Biochem Pharmacol; 2006 Sep; 72(6):693-700. PubMed ID: 16844093
[TBL] [Abstract][Full Text] [Related]
29. Impact of oxaliplatin and a novel DACH-platinum complex in the gene expression of HCT116 colon cancer cells.
Pang SK; Yu CW; Guan H; Au-Yeung SC; Ho YP
Oncol Rep; 2008 Nov; 20(5):1269-76. PubMed ID: 18949432
[TBL] [Abstract][Full Text] [Related]
30. Relevance of copper transporter 1 and organic cation transporters 1-3 for oxaliplatin uptake and drug resistance in colorectal cancer cells.
Buß I; Hamacher A; Sarin N; Kassack MU; Kalayda GV
Metallomics; 2018 Mar; 10(3):414-425. PubMed ID: 29417972
[TBL] [Abstract][Full Text] [Related]
31. Association between tubular toxicity of cisplatin and expression of organic cation transporter rOCT2 (Slc22a2) in the rat.
Yonezawa A; Masuda S; Nishihara K; Yano I; Katsura T; Inui K
Biochem Pharmacol; 2005 Dec; 70(12):1823-31. PubMed ID: 16242669
[TBL] [Abstract][Full Text] [Related]
32. Expression of human organic cation transporter 3 in kidney carcinoma cell lines increases chemosensitivity to melphalan, irinotecan, and vincristine.
Shnitsar V; Eckardt R; Gupta S; Grottker J; Müller GA; Koepsell H; Burckhardt G; Hagos Y
Cancer Res; 2009 Feb; 69(4):1494-501. PubMed ID: 19190342
[TBL] [Abstract][Full Text] [Related]
33. Oxaliplatin in treatment of the cisplatin-resistant MKN45 cell line of gastric cancer.
Tozawa K; Oshima T; Kobayashi T; Yamamoto N; Hayashi C; Matsumoto T; Miwa H
Anticancer Res; 2008; 28(4B):2087-92. PubMed ID: 18751380
[TBL] [Abstract][Full Text] [Related]
34. PKM2 Subcellular Localization Is Involved in Oxaliplatin Resistance Acquisition in HT29 Human Colorectal Cancer Cell Lines.
Ginés A; Bystrup S; Ruiz de Porras V; Guardia C; Musulén E; Martínez-Cardús A; Manzano JL; Layos L; Abad A; Martínez-Balibrea E
PLoS One; 2015; 10(5):e0123830. PubMed ID: 25955657
[TBL] [Abstract][Full Text] [Related]
35. Luteolin potentiates the sensitivity of colorectal cancer cell lines to oxaliplatin through the PPARγ/OCTN2 pathway.
Qu Q; Qu J; Guo Y; Zhou BT; Zhou HH
Anticancer Drugs; 2014 Oct; 25(9):1016-27. PubMed ID: 25075794
[TBL] [Abstract][Full Text] [Related]
36. Effects of a combretastatin A4 analogous chalcone and its Pt-complex on cancer cells: A comparative study of uptake, cell cycle and damage to cellular compartments.
Zoldakova M; Kornyei Z; Brown A; Biersack B; Madarász E; Schobert R
Biochem Pharmacol; 2010 Nov; 80(10):1487-96. PubMed ID: 20709029
[TBL] [Abstract][Full Text] [Related]
37. Overexpression of bone morphogenetic protein 4 enhances the invasiveness of Smad4-deficient human colorectal cancer cells.
Deng H; Ravikumar TS; Yang WL
Cancer Lett; 2009 Aug; 281(2):220-31. PubMed ID: 19321257
[TBL] [Abstract][Full Text] [Related]
38. Expression of organic cation transporter SLC22A16 in human endometria.
Sato N; Ito K; Onogawa T; Akahira J; Unno M; Abe T; Niikura H; Yaegashi N
Int J Gynecol Pathol; 2007 Jan; 26(1):53-60. PubMed ID: 17197897
[TBL] [Abstract][Full Text] [Related]
39. Establishment and gene analysis of an oxaliplatin-resistant colon cancer cell line THC8307/L-OHP.
Tang H; Liu YJ; Liu M; Li X
Anticancer Drugs; 2007 Jul; 18(6):633-9. PubMed ID: 17762391
[TBL] [Abstract][Full Text] [Related]
40. A comparison of the platinum analogues in bladder cancer cell lines.
Powles T; Perry J; Shamash J; Liu W; Oliver T; Joel S
Urol Int; 2007; 79(1):67-72. PubMed ID: 17627172
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
